Loading...
Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
Eliglustat is a first‐line oral therapy for adults with Gaucher disease type 1 (GD1) with extensive, intermediate, or poor CYP2D6‐metabolizer phenotypes (90% of patients). We report real‐world outcomes after 2 years of eliglustat therapy in the International Collaborative Gaucher Group Gaucher Regis...
Na minha lista:
| Udgivet i: | Am J Hematol |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7497238/ https://ncbi.nlm.nih.gov/pubmed/32438452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25875 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|